Bordeaux, September 25, 2023 – 6:00 p.m. CEST – Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its results for the first half of 2023 and provides an update on its development.
Pier Vincenzo Piazza, Managing Director of Aelis Farma, declares: “We are very satisfied with the progress made during the first six months of 2023. Thanks to the efficiency, motivation and dedication of our teams, the steps key clinical trials announced have been achieved, allowing us to successfully achieve the ambitious objectives that we have set for ourselves, in particular for our two “first-in-class” drug candidates, AEF0117 and AEF0217. For the second half of 2023, the execution of our roadmap for these key assets remains our priority, but we will also evaluate additional indications such as Phelan-McDermid syndrome (PMS) for AEF0217 and expand our pipeline […]. »
To receive all AELIS FARMA financial information in real time, request it by email to [email protected]. Your registration will be immediate.